RaQualia Pharma Inc
TSE:4579

Watchlist Manager
RaQualia Pharma Inc Logo
RaQualia Pharma Inc
TSE:4579
Watchlist
Price: 1 023 JPY 2.2% Market Closed
Market Cap: 25B JPY

Gross Margin
RaQualia Pharma Inc

74.6%
Current
85%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
74.6%
=
Gross Profit
2.3B
/
Revenue
3B

Gross Margin Across Competitors

No Stocks Found

RaQualia Pharma Inc
Glance View

Market Cap
25B JPY
Industry
Pharmaceuticals

RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. The company is headquartered in Nagoya, Aichi-Ken and currently employs 67 full-time employees. The company went IPO on 2011-07-20. The firm is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The firm is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.

Intrinsic Value
706.4 JPY
Overvaluation 31%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
74.6%
=
Gross Profit
2.3B
/
Revenue
3B
What is the Gross Margin of RaQualia Pharma Inc?

Based on RaQualia Pharma Inc's most recent financial statements, the company has Gross Margin of 74.6%.

Back to Top